ISSN Approved Journal || eISSN: 2582-8185 || CODEN: IJSRO2 || Impact Factor 8.2 || Google Scholar and CrossRef Indexed
Fast Publication within 48 hours || Low Article Processing Charges || Peer Reviewed and Referred Journal || Free Certificate
Tamoxifen and serotonin reuptake inhibitors: Risks and benefits of co-administration
Centro Universitário Alfredo Nasser.
Review
International Journal of Science and Research Archive, 2024, 13(02), 3894-3899.
Article DOI: 10.30574/ijsra.2024.13.2.2645
Publication history:
Received on 23 November 2024; revised on 28 December 2024; accepted on 31 December 2024
Abstract:
Tamoxifen citrate is a nonsteroidal compound belonging to the triphenylethylene class, characterized by a complex spectrum of pharmacological effects, acting as an estrogen antagonist or agonist depending on the tissue. In breast cancer patients, tamoxifen predominantly exerts an anti-estrogenic action on tumor tissue by inhibiting the binding of estrogen to its receptors. Tamoxifen is metabolized in the liver by the cytochrome P450 enzymatic system, resulting in active metabolites. The CYP2D6 enzyme plays a crucial role in the metabolism of approximately 25% of exogenous drugs, including tamoxifen, being considered the primary enzyme involved in the bioactivation of this therapeutic agent. This study aims to understand the metabolism of tamoxifen mediated by the cytochrome P450 system, particularly CYP2D6, which is essential for optimizing its clinical use and allowing treatment personalization based on the patient’s individual metabolic profile. This literature review was conducted through the analysis of articles published in the last five years or of significant impact in the field, focusing on drug interactions and the management of depressive symptoms during oncological treatment. Measures are essential to mitigate the risks associated with drug interactions. Some studies recommend reviewing pharmacotherapy, considering not only antineoplastic drugs but also complementary, alternative therapies and the use of over-the-counter medications to reduce the number of substances administered. Furthermore, the early identification of potential interactions is crucial, enabling appropriate and proactive clinical management. Thus, an in-depth understanding of CYP2D6 pharmacogenomics and the adoption of evidence-based clinical strategies are indispensable for optimizing tamoxifen treatment, preserving its efficacy, and minimizing the risks associated with drug interactions
Keywords:
Tamoxifen; Drug interaction; Selective serotonin reuptake inhibitors; Breast cancer
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
